Production of Kinanthraquinone D with Antimalarial Activity by Heterologous Gene Expression and Biotransformation in Streptomyces lividans TK23

Katsuyuki Sakai,Yushi Futamura,Toshihiko Nogawa,Yuzhu Zhao,Hiroyuki Koshino,Hiroyuki Osada,Shunji Takahashi
DOI: https://doi.org/10.1021/acs.jnatprod.3c01076
IF: 5.1
2024-02-27
Journal of Natural Products
Abstract:Two new compounds, kinanthraquinone C (<b>1</b>) and kinanthraquinone D (<b>2</b>), were isolated along with two known compounds, kinanthraquinone (<b>3</b>) and kinanthraquinone B (<b>4</b>), produced by the heterologous expression of the <i>kiq</i> biosynthetic gene cluster and its pathway-specific regulator, <i>kiqA</i>, in <i>Streptomyces lividans</i> TK23. The chemical structures of compounds <b>1</b> and <b>2</b> were determined using mass spectrometry and nuclear magnetic resonance analyses. To examine a biosynthetic pathway of compounds <b>1</b> and <b>2</b>, incubation experiments were conducted using <i>S. lividans</i> TK23 to supply the compounds <b>3</b> and <b>4</b>. These experiments indicated that compounds <b>3</b> and <b>4</b> were converted to compounds <b>2</b> and <b>1</b>, respectively, by the endogenous enzymes of <i>S. lividans</i> TK23. Compounds <b>2</b>, <b>3</b>, and <b>4</b> had antimalarial activities at half-maximal inhibitory concentration values of 0.91, 1.2, and 15 μM, respectively, without cytotoxicity up to 30 μM.
plant sciences,chemistry, medicinal,pharmacology & pharmacy
What problem does this paper attempt to address?